{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-232477","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2023-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.789533+00:00","generated_at":"2026-06-10T21:45:02.229921+00:00","sec_items":["5.02","5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"UroGen Pharma shareholders approve 2017 Plan amendment, elect directors, ratify auditor","bullets":["Elected eight directors including Arie Belldegrun, Elizabeth Barrett, Cynthia M. Butitta, and Fred E. Cohen.","Approved amendment to 2017 Equity Incentive Plan increasing authorized shares by 450,000.","Approved grant of Performance Stock Units to CEO under the amended plan (13,115,279 for, 3,363,390 against).","Advisory say-on-pay passed with 13,668,197 for, 3,118,618 against, 35,305 abstentions.","Ratified PricewaterhouseCoopers LLP as independent auditor for next fiscal year (22,507,002 for, 16,731 against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-232477","json":"https://secwatch.observer/filing/0001193125-23-232477.json","markdown":"https://secwatch.observer/filing/0001193125-23-232477.md","text":"https://secwatch.observer/filing/0001193125-23-232477.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523232477/0001193125-23-232477-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523232477/d485257d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:45:02.229921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"265e9a48a7f916673008467a03e8357f5256829f","claim":"UroGen Pharma Ltd. shareholders approved Election of Directors.","evidence_excerpt":"Proposal 1 – Election of Directors The shareholders elected the following eight individuals to serve as directors until the Company’s next annual meeting of shareholders and until their successors are elected.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523232477/0001193125-23-232477-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"34e8b641055fe897d52672d01a979451f82c7885","claim":"UroGen Pharma Ltd. shareholders approved Engagement of PricewaterhouseCoopers LLP as independent auditor.","evidence_excerpt":"Proposal 5 - Engagement of PricewaterhouseCoopers LLP as independent auditor. The shareholders approved the engagement of PricewaterhouseCoopers LLP as the Company’s independent auditor until the Company’s 2024 annual meeting of shareholders.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523232477/0001193125-23-232477-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"459e8b9a1784c6abe4913b9d6f5797cbcdeb294f","claim":"UroGen Pharma Ltd. shareholders approved Performance Stock Units grant to CEO.","evidence_excerpt":"Proposal 3 – Performance Stock Units The shareholders approved a grant of Performance Stock Units to the Company’s Chief Executive Officer under the 2017 Amended Plan.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523232477/0001193125-23-232477-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"52c101979e5e1db69606dc3aa1820f4ef0144037","claim":"UroGen Pharma Ltd. shareholders approved Advisory vote on the compensation of the Company’s named executive officers.","evidence_excerpt":"Proposal 4 - Advisory vote on the compensation of the Company’s named executive officers. On an advisory basis, the shareholders approved the compensation paid to the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annual Meeting.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523232477/0001193125-23-232477-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"ff541c981c6fefe722df09971c076c37cd5298b8","claim":"UroGen Pharma Ltd. shareholders approved 2017 Amended Plan.","evidence_excerpt":"Proposal 2 – 2017 Amended Plan. The shareholders approved the 2017 Amended Plan.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523232477/0001193125-23-232477-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}